GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study

鼻咽癌 医学 肿瘤科 癌 内科学 放射治疗
作者
Lin‐Quan Tang,Sai-Lan Liu,Muh‐Hwa Yang,Hui‐Ching Wang,Yujuan Zhou,Kunyu Yang,Qun Li,Mun Ngah Hui,Xiaozhong Chen,Yi‐Shing Leu,Li‐Tzong Chen,Li-Ting Liu,Shan-Shan Guo,Qiu-Yan Chen,Shuang Wang,Hua-Qiang Zhu,Hai-Ge Shen,Yu Wang,Ye Guo,Hai‐Qiang Mai
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (16): 3424-3432 被引量:5
标识
DOI:10.1158/1078-0432.ccr-25-0085
摘要

PURPOSE: GFH018 is a novel TGF-β type I receptor inhibitor, which has been shown to potentiate the antitumor effect of anti-PD-1/PD-L1 blockade. This study aimed to evaluate the safety and efficacy of GFH018 plus toripalimab in patients with recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: This phase Ib/II study included patients with specific solid tumors who had failed at least one prior line of standard therapy. Patients received GFH018 (40 or 80 mg) twice a day for 14 days on/14 days off, combined with toripalimab (3 mg/kg) intravenously every 2 weeks on a 28-day cycle. Treatment continued until disease progression or intolerable toxicity. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), duration of response (DoR), and safety. RESULTS: Forty-six patients with R/M NPC were accrued. The ORR was 26.1% [90% confidence interval (CI), 15.8%-38.8%], and the disease control rate (DCR) was 43.5% (90% CI, 31.0%-56.6%). The median PFS was 2.0 months (90% CI, 1.8-8.9), and the median DoR was 7.6 months (90% CI, 5.6-not reached). In patients without prior immune checkpoint inhibitor (ICI) treatment, the ORR was 40% (90% CI, 23.6%-58.3%) and the DCR was 60% (90% CI, 41.7%-76.4%). The median PFS was 9.0 months (90% CI, 1.9-not reached), and the median DoR was not reached. In patients previously exposed to ICIs, the ORR was 9.5% (90% CI, 1.7%-27.1%) and the DCR was 23.8% (90% CI, 9.9%-43.7%). High parenchymal CD8+ T-cell density correlated with better PFS in these patients. Data from other solid tumor cohorts will be reported in future analyses. CONCLUSIONS: The combination of GFH018 and toripalimab showed a manageable toxicity profile and durable antitumor activity in patients with R/M NPC, especially those without prior ICI exposure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小于完成签到,获得积分10
2秒前
2秒前
高兴的苞络完成签到,获得积分10
2秒前
2秒前
3秒前
4秒前
葡萄冻冻完成签到 ,获得积分10
4秒前
5秒前
5秒前
hong的应助被科研通管家采纳,获得10
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
在水一方的应助被科研通管家采纳,获得10
5秒前
充电宝的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
徐进完成签到,获得积分10
5秒前
5秒前
6秒前
隐形曼青的应助被科研通管家采纳,获得10
6秒前
小二郎的应助被科研通管家采纳,获得10
6秒前
syvshc的应助被科研通管家采纳,获得10
6秒前
酷波er的应助被李刚采纳,获得10
6秒前
在水一方的应助被科研通管家采纳,获得10
6秒前
喷火娃的应助被科研通管家采纳,获得10
6秒前
梵蒂冈完成签到 ,获得积分10
6秒前
小马甲的应助被科研通管家采纳,获得10
6秒前
6秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
葉落葉飄完成签到,获得积分10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
情怀的应助被科研通管家采纳,获得10
7秒前
7秒前
彭于晏的应助被科研通管家采纳,获得10
7秒前
今后的应助被科研通管家采纳,获得10
7秒前
小二郎的应助被科研通管家采纳,获得10
7秒前
泡泡玛特发布了新的文献求助10
8秒前
大模型的应助被科研通管家采纳,获得10
8秒前
共享精神的应助被科研通管家采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187612
求助须知:如何正确求助?哪些是违规求助? 9575734
关于积分的说明 21842594
捐赠科研通 7785476
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559478
邀请新用户注册赠送积分活动 2481952